Showing 341 - 360 results of 146,371 for search '(( 5 ((ppm decrease) OR (mean decrease)) ) OR ( a ((non decrease) OR (a decrease)) ))', query time: 1.15s Refine Results
  1. 341
  2. 342

    SUI-sEVs decreased the proliferation of fibroblasts. by Xiaoyan Sun (28501)

    Published 2021
    “…<p>Fibroblasts were cultured with control medium or medium containing SUI-sEVs or medium containing non SUI-sEVs for 24, 48 and 72h, respectively. (A) Cell proliferation was determined with a CCK-8 assay. …”
  3. 343

    Regenerating axons are increased by ATRA and decreased by clodronate. by Valeria De La Rosa-Reyes (6658613)

    Published 2021
    “…<p>(A—E) Confocal images of immunohistochemical staining of growing axons with anti-GAP43 antibody (green), in longitudinal sections of the optic nerve at 2 weeks after axotomy. …”
  4. 344

    Depletion of ERp29 decreases cellular Proinsulin. by Jeffrey Viviano (8871581)

    Published 2020
    “…<p>Min-6 cells were transfected with ERp29-targeting siRNA or with a non-targeting control siRNA. (A) The resulting depletion of ERp29 and its effect on Proinsulin abundance were then assayed by immunoblot. …”
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351

    Decrease of p38 MAPK phosphorylation in HL60 and KG1a cells exposed to 5-Fluorouridine (FUrd) after cell pretreatment with p38 MAPK pathway inhibitor SB202190. by Sabine Matou-Nasri (2938941)

    Published 2022
    “…<p>The KG1a and HL60 cells were pre-treated with 10 μM SB202190 for 2 h incubation then followed by the cell treatment with 10 μM of FUrd. …”
  12. 352

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  13. 353
  14. 354
  15. 355
  16. 356

    Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx by Ha Young Jang (1522204)

    Published 2022
    “…</p>Result<p>We followed-up (median: 5.6 years) 188,906 matched patients (94,453 LTRA users and 94,453 non-users). LTRA use was associated with a decreased risk of cancer (adjusted HR [aHR] = 0.85, 95% confidence interval [CI] = 0.83–0.87). …”
  17. 357
  18. 358
  19. 359
  20. 360